argenx SE (NASDAQ:ARGX) Shares Sold by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans trimmed its holdings in shares of argenx SE (NASDAQ:ARGX - Free Report) by 11.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,065 shares of the company's stock after selling 4,287 shares during the period. Thrivent Financial for Lutherans owned about 0.05% of argenx worth $20,324,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of the stock. Whipplewood Advisors LLC purchased a new position in argenx during the fourth quarter worth $37,000. Global Retirement Partners LLC boosted its stake in shares of argenx by 369.2% during the fourth quarter. Global Retirement Partners LLC now owns 61 shares of the company's stock valued at $38,000 after acquiring an additional 48 shares during the last quarter. Jones Financial Companies Lllp increased its position in argenx by 1,016.7% during the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company's stock worth $41,000 after purchasing an additional 61 shares in the last quarter. Farther Finance Advisors LLC raised its stake in argenx by 38.2% in the 4th quarter. Farther Finance Advisors LLC now owns 76 shares of the company's stock valued at $47,000 after purchasing an additional 21 shares during the last quarter. Finally, Venturi Wealth Management LLC acquired a new stake in shares of argenx during the 4th quarter worth about $66,000. 60.32% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on ARGX shares. JMP Securities upped their price objective on shares of argenx from $606.00 to $696.00 and gave the company a "market outperform" rating in a research note on Tuesday, January 14th. William Blair restated an "outperform" rating on shares of argenx in a report on Friday, February 28th. Deutsche Bank Aktiengesellschaft upgraded argenx from a "sell" rating to a "hold" rating in a research note on Wednesday, March 12th. Robert W. Baird lifted their price target on argenx from $650.00 to $680.00 and gave the company a "neutral" rating in a report on Tuesday, March 4th. Finally, Wells Fargo & Company increased their price objective on shares of argenx from $723.00 to $741.00 and gave the stock an "overweight" rating in a report on Friday, February 28th. Three analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $687.00.

Remove Ads

argenx Stock Down 0.4 %

Shares of ARGX traded down $2.43 during mid-day trading on Tuesday, reaching $605.52. 221,831 shares of the stock traded hands, compared to its average volume of 282,872. The firm has a market cap of $36.79 billion, a price-to-earnings ratio of -688.09 and a beta of 0.59. The stock has a fifty day simple moving average of $633.44 and a 200 day simple moving average of $600.67. argenx SE has a 12-month low of $352.77 and a 12-month high of $678.21.

argenx (NASDAQ:ARGX - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported $1.58 EPS for the quarter, topping analysts' consensus estimates of $0.98 by $0.60. The firm had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. On average, equities research analysts expect that argenx SE will post 3.13 earnings per share for the current fiscal year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.